SolGel Technologies (SLGL)
(Delayed Data from NSDQ)
$0.85 USD
0.00 (0.05%)
Updated May 3, 2024 03:59 PM ET
After-Market: $0.84 -0.01 (-1.22%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.85 USD
0.00 (0.05%)
Updated May 3, 2024 03:59 PM ET
After-Market: $0.84 -0.01 (-1.22%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Zacks News
Bausch Health (BHC) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of -21.33% and 1.39%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Generation Bio Co. (GBIO) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -29.27% and 5.64%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Supernus Pharmaceuticals (SUPN) Lags Q4 Earnings Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of -95.12% and 6.39%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Dr. Reddy's Laboratories, Amphastar Pharmaceuticals and Sol-Gel Technologies
by Zacks Equity Research
Dr. Reddy's Laboratories, Amphastar Pharmaceuticals and Sol-Gel Technologies are part of the Zacks Industry Outlook article.
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
by Sundeep Ganoria
The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to RDY, AMPH and SLGL.
Sol-Gel Technologies Ltd. (SLGL) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sol-Gel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of 15.38% and 61.68%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Personalis (PSNL) delivered earnings and revenue surprises of 10.71% and 0.29%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sol-Gel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of -86.36% and 51.60%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Sol-Gel Technologies Ltd. (SLGL) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sol-Gel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of -92.31% and 94.60%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Homology Medicines (FIXX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Homology Medicines (FIXX) delivered earnings and revenue surprises of -17.65% and 23.62%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of 92.11% and 6.80%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Dr. Reddy's, Amphastar Pharmaceuticals and Sol-Gel Technologies
by Zacks Equity Research
Dr. Reddy's, Amphastar Pharmaceuticals and Sol-Gel Technologies have been highlighted in this Industry Outlook article.
3 Generic Drug Stocks to Watch Amid Inflation Pressures
by Sundeep Ganoria
The impact of inflationary headwinds and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and SLGL.
SolGel Technologies Ltd. (SLGL) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of -114.29% and 92.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Bausch Health (BHC) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of -17.39% and 2.21%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Sol-Gel
by Zacks Equity Research
Teva, Dr. Reddy's and Sol-Gel have been highlighted in this Industry Outlook article.
3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure
by Sundeep Ganoria
The impact of COVID-19 and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to TEVA, RDY and SLGL.
SolGel Technologies Ltd. (SLGL) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of 90% and 27.46%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
SolGel Technologies Ltd. (SLGL) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of 20% and 99.85%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Amphastar Pharmaceuticals (AMPH) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of 42.42% and 8.83%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Generation Bio Co. (GBIO) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -17.31% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: SolGel Technologies Ltd. (SLGL) Q1 Earnings Expected to Decline
by Zacks Equity Research
SolGel Technologies Ltd. (SLGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure
by Indrajit Bandyopadhyay
The impact of COVID-19 and continued pricing pressure on the Zacks Medical-Generic Drugs industry remains. New product launches may provide some respite for BHC, AMPH and SLGL.
Bausch Health (BHC) Beats Q4 Earnings Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of 17.59% and 0.45%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
SolGel Technologies Ltd. (SLGL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
SolGel Technologies Ltd. (SLGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.